Close Menu
Skip to main content
GenomeWeb
360Dx
Precision Oncology News
Precision Oncology News
*
*
Show password
Forgot your password?
Subscribe
Contains all of these words:
Business & Policy
Business News
Regulatory News
Reimbursement
Biomarkers
BRCA
EGFR
HER2
KRAS
BRAF
ROS1
ALK
PD-L1
Cancer Specialties
Breast Cancer
Lung Cancer
Colorectal Cancer
Prostate Cancer
Ovarian Cancer
Brain Cancer
Melanoma
Pediatric Cancer
Oncology Trends
Next-Generation Sequencing
Minimal Residual Disease
Microsatellite Instability Testing
Immunotherapy
Liquid Biopsy
Resources
Webinars
White Papers
Conferences & Events
Menu
Home
›
About Us
›
Our Staff
›
Allan Nixon
Allan Nixon
Director of Business Development, Premium Content
Phone Number
+1-212-651-5623
Email
[email protected]
Breaking
News
HalioDx, Kite Pharma Extend Biomarker Collaboration
European Regulators Recommend Approval of Roche Treatment for HER2-Positive Breast Cancer
Melanoma Patients See Magnified Benefit From Targeted Treatment Combo in Five-Year Outcomes Data
FDA Clears NantHealth Tumor-Normal Whole-Exome Test
Lucence Diagnostics, MEDx Partner on Companion Diagnostic Cancer Tests in China
Colorectal Cancers Dial up Mutability in Response to Targeted Treatments
